A randomized, placebo-controlled, double-blind comparative study to evaluate the efficacy of the antioxidant N-acetylcysteine (NAC) for intervertebral disc degeneration.

Watanabe Kota0 个研究点目标入组 60 人开始时间: 2019年3月27日最近更新: 2024年4月23日

试验速览

暂无简介。

•1) Patients with lumbar disc degeneration based on images(Pfirrmann grade: 3, 4) and neurological findings
•2) Age From 20 years old to less than 65 years old
•3) During the study period, anti-inflammatory / analgesic agents (NSAIDs including COX-2 inhibitors, an extract from Inflamed cutaneous tissue of rabbits inoculated with Vaccinia Virus (neurotropin), antioxidant vitamin E formulation(yubera), as well as steroidal agents (oral preparation and injection)), those who agree to discontinue the use.

•1) Patients with complications such as severe heart, lung, liver, and blood diseases
•2) Patients who received surgical treatment judged by the attending physician to affect the exam
•3) Patients whose ALT / AST values before administration exceed 3 times the institution standard value
•4) Currently, supplements containing NAC or NAC or supplements with antioxidant action (vitamin E) ingested
•5) Patients who are allergic to drugs including NAC
•6) Women who are pregnant, nursing, maybe pregnant or prefer pregnant during treatment
•7) Patients who have undergone spinal surgery in the past
•8) Others, patients who are judged to be unacceptable as subjects of this study by the investigator or shared medical doctor

发起方

Watanabe Kota